|
Art. 63
1 For class III devices and for implantable devices, other than custom-made or investigational devices, the manufacturer must draw up a summary of safety and clinical performance. 2 The summary of safety and clinical performance shall be written in a way that is clear to the intended user and, if relevant, to the patient. 3 The minimum content of the summary is governed by Article 32, Paragraph 32 EU-MDR101. 4 The draft summary must be submitted, together with the documentation, to the designated body involved in the conformity assessment for validation by that body.102 5 The manufacturer shall publish the summary after it has been validated.103 6 The manufacturer must mention on the label or instructions for use where the summary is available. 101 See the footnote to Art. 4 para. 1 let. f. 102 Amended by Annex 5 No 1 of the O of 4 May 2022 on In Vitro Diagnostic Medical Devices, in force since 26 May 2022 (AS 2022 291). 103 Amended by No I of the O of 19 May 2021, in force since 26 May 2021 (AS 2021 281). |